Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ballard

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Birth Defects Research|August 28, 2024
Absence of developmental and reproductive toxicity in rats, rabbits, and zebrafish embryos exposed to antimalarial drug cabamiquineAndreas Gado, Philip Hewitt, Peter Ballard, et al.
Chemmedchem|June 5, 2023
Metabolism of (R)-Praziquantel versus the Activation of a Parasite Transient Receptor Potential Melastatin Ion ChannelLukas Friedrich, Sang-Kyu Park, Peter Ballard, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2005
5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinasePeter Ballard, Robert H Bradbury, Laurent F A Hennequin, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2006
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokineticsPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 ReceptorsBernard Barlaam, Judith Anderton, Peter Ballard, et al.
Journal of Medicinal Chemistry|March 5, 2015
Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesisJason G Kettle, Peter Ballard, Catherine Bardelle, et al.
Bioorganic & Medicinal Chemistry Letters|March 7, 2006
Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitorsLaurent F A Hennequin, Peter Ballard, F Tom Boyle, et al.
Bioorganic & Medicinal Chemistry Letters|October 27, 2009
Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivoRichard W A Luke, Peter Ballard, David Buttar, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinaseBernard Barlaam, David G Acton, Peter Ballard, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2005
Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocketPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Birth Defects Research|August 28, 2024
Absence of developmental and reproductive toxicity in rats, rabbits, and zebrafish embryos exposed to antimalarial drug cabamiquineAndreas Gado, Philip Hewitt, Peter Ballard, et al.
Chemmedchem|June 5, 2023
Metabolism of (R)-Praziquantel versus the Activation of a Parasite Transient Receptor Potential Melastatin Ion ChannelLukas Friedrich, Sang-Kyu Park, Peter Ballard, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2005
5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinasePeter Ballard, Robert H Bradbury, Laurent F A Hennequin, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2006
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokineticsPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 ReceptorsBernard Barlaam, Judith Anderton, Peter Ballard, et al.
Journal of Medicinal Chemistry|March 5, 2015
Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesisJason G Kettle, Peter Ballard, Catherine Bardelle, et al.
Bioorganic & Medicinal Chemistry Letters|March 7, 2006
Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitorsLaurent F A Hennequin, Peter Ballard, F Tom Boyle, et al.
Bioorganic & Medicinal Chemistry Letters|October 27, 2009
Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivoRichard W A Luke, Peter Ballard, David Buttar, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinaseBernard Barlaam, David G Acton, Peter Ballard, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2005
Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocketPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
Pageof 3